When comparing the imputed sensitivity scores of drugs, HCC patients with lower PCDI scores demonstrated heightened sensitivity to oxaliplatin, whereas those with higher PCDI scores exhibited heightened sensitivity to inhibitors of cell mitosis and proliferation, such as paclitaxel, docetaxel, and vinblastine, as well as certain targeted drugs and small molecule inhibitors such as cediranib, bortezomib, MIM1, MK-1775, and WIKI4. The gene discussed is MIMT1; the disease is hepatocellular carcinoma.